On the other hand, anti-HER2 mAb (trastuzumab) conjugated to immunomicelles does not indicate meaningful anti-cancer activity toward HER2-positive stomach cancer in comparison with the combined use of anti-HER2 mAb and NC-6300 in gastric cancer [223]. This evidence concerns the gene ERBB2 and gastric cancer.